LUND, SWEDEN--(Marketwire - August 06, 2009) - * Laquinimod -- BRAVO Phase III trial fully enrolled
* 57-57 -- explorative clinical trial initiated * RhuDex™ -- preclinical tests in progress * ANYARA -- Phase III trial fully enrolled * TASQ -- Phase II trial fully enrolled * ISI - target molecule for Q compounds published * Net sales of SEK 5.2 M (5.8) * Operating loss of SEK 118.5 M (loss: 104.7) * Loss after tax of SEK 118.6 M (loss: 99.3) * Loss per share for the period of SEK 2.22 (loss 2.07) * Implemented rights issue contributed approximately SEK 249 M * Number of shares at the end of the period (incl. warrants), 65,052,238
This report is also available at www.activebiotech.com
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
For further information, please contact:
Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95
Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54
Hans Kolam
CFO
Tel: +46 (0)46-19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
